Clinical Trial Update: Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing neoadjuvant nivolumab plus relatlimab (Opdualag) versus nivolumab alone in resectable high-risk basal cell carcinoma; currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Basal Cell Carcinoma | Phase 2 | Status: RECRUITING